Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

November 17, 2023 updated by: Michael J. Telch, University of Texas at Austin

Use of Cannabidiol (CBD) Oil in the Treatment of PTSD: A Placebo-Controlled Randomized Clinical Trial

The overarching objective of the proposed project is to test the clinical efficacy of CBD in the treatment of post-traumatic stress disorder using a rigorous double-blind randomized clinical trial methodology. Participants (n=150) meeting full DSM-5 criteria for post-traumatic stress disorder (PTSD) will be randomized to one of 3 treatment arms: (a) CBD -Isolate; (b) CBD-Broad Spectrum; (c) Placebo oil.

We predict that patients receiving CBD isolate or CBD Broad Spectrum will show significantly greater improvements in PTSD symptoms and functional impairment at the posttreatment and one-month follow-up relative to patients receiving placebo oil. Additionally, we expect that patients receiving CBD Broad Spectrum will show significantly greater improvements relative to patients receiving CBD Isolate.

Study Overview

Status

Suspended

Conditions

Intervention / Treatment

Detailed Description

Background and Significance of the Proposed Project

Over 80% of Americans are exposed to a significant trauma sometime during their lifetime and approximately 7% will meet for a threshold diagnosis of posttraumatic stress disorder. PTSD is the most costly anxiety-related disorder and confers significant interference in work, social functioning, increased risk for other physical and mental health problems, and a four-fold increase in suicide rates compared to the general population.

Over the past two decades, trauma-focused psychotherapies for PTSD have been shown to outperform more traditional supportive psychotherapy or pharmacotherapy and have become the first line treatment for PTSD. Despite these advances, trauma focused treatments such as prolonged exposure therapy (PE) are associated with high rates of treatment refusal, and among those who do enter treatment, approximately 25% drop-out. These data highlight the need to develop PTSD treatment strategies that are both effective and more palatable to patients.

More recently, there's been considerable excitement in the press over the potential therapeutic use of cannabidiol (CBD) products in the treatment of a variety of physical and mental health problems.( Delta-9-tetrahydrocannabinol (delta-9 THC) is still illegal in most states because of its psychoactive abuse potential. In contrast, cannabidiol (CBD) does not convert to THC in the body and has negligible side effects relative to main stream psychiatric drugs (benzodiazepines and antidepressants) commonly prescribed for the treatment of PTSD. Mounting evidence from studies with rodents suggests that CBD may confer significant promising health-related benefits including anti-inflammatory, pain-relieving, anti-cancer, memory enhancement, and facilitation of fear extinction (see White for a recent review).

The biggest success story for CBD use in humans to date comes from controlled randomized clinical trials demonstrating a 50% or more reduction in previously intractable seizures in children suffering from Dravet syndrome and Lennox-Gastaut syndrome. Moreover, several controlled clinical trials have shown promising findings in reducing psychotic symptoms among patients with schizophrenia and among young adults displaying THC-induced psychosis.

Preliminary Evidence that CBD may offer promise in the treatment of anxiety-related disorders has started to emerge. A small pilot trial with 24 patients presenting with social anxiety disorder found that relative to placebo, a single dose of 100 mg of CBD oil led to lower levels of anxiety, cognitive impairment, and discomfort in their actual speech performance as well as their anxiety before the speech. Unfortunately, human treatment studies for anxiety-related problems is limited almost exclusively to single dose effects on an anxiety challenge task. Studies are clearly needed to assess the effects of multi-dose CBD treatments across the full spectrum of trauma and anxiety-related disorders such as posttraumatic stress disorder.

PROJECT AIMS

The overarching objective of the proposed project is to test the clinical efficacy of CBD in the treatment of posttraumatic stress disorder using a rigorous double-blind randomized clinical trial methodology.

Specific aims of the project include:

  1. Compare the efficacy of an 8-week multi-dose regimen of two CBD oil formulations (CBD Isolate (300 mg/day) and CBD Broad Spectrum) relative to placebo oil in reducing PTSD symptoms at the posttreatment and one-month follow-up.

    We predict that patients receiving CBD oil (CBD isolate or CBD Broad Spectrum) will show significantly greater improvement in PTSD symptoms and functional impairment at post-treatment and one-month follow-up relative to patients receiving placebo oil.

    We also predict that patients receiving the CBD Broad Spectrum formulation will show significantly greater improvement in PTSD symptoms and functional impairment relative to patients receiving CBD Isolate.

  2. Examine predictors of patients' clinical response to the various treatment combinations.

    We expect that the superiority of CBD relative to placebo will be more pronounced for patients showing more severe PTSD symptoms at baseline.

  3. Examine the perceived acceptability and patients' side effects profile of 8 weeks of daily CBD oil ingestion.

We expect that CBD-treated patients will show equivalent levels of side effects as those receiving placebo oil.

STUDY METHODS AND PROCEDURES

Participant Recruitment: 150 participants between the ages of 18 and older will be recruited through several outlets including notices posted on campus, announcements on our research laboratory website and national organizations related to PTSD and its treatment.

Participant Screening: Participants will undergo a two-stage screening procedure. Stage 1 will be a brief structured web-based screening interview. Stage 2 will be a web-based, self-report version of the Mini-International Neuropsychiatric Interview (MINI). Participants meeting the following inclusion and exclusion enrollment criteria will be invited to take part in the study (see below).

NOTE: ALL STUDY PROCEDURES ARE COMPLETED AT PARTICIPANTS' HOMES. NO VISITS TO OUR RESEARCH LABORATORY ARE REQUIRED.

Inclusion/Exclusion Criteria:

  1. Meets for a current DSM-5 diagnosis of PTSD as their "primary" mental disorder
  2. Age between 18+
  3. Fluent in English
  4. Willingness to provide signed informed consent online
  5. No history of a suicide attempt in the past 6 months
  6. No history of psychosis within the past 6 months

9. No history of current alcohol or substance use disorder within the past month.

10. No current medical problems that would preclude safe ingestion of CBD oil 11. Willingness to refrain from other forms of Cannabis use during the study period 12. Has home access to the internet. 13. No history of adverse reaction to CBD. 14. No allergy to coconut oil.

Participant Informed Consent:

All study participants will be consented by the study coordinator or a doctoral student research assistant. The online informed consent document will provide participants with information regarding the aims of the project, what they will be asked to do, any anticipated risks or benefits associated with participating in the study, as well as a clear statement that their participation is voluntary and that they may discontinue participation at any time.

Study Design Overview: The research plan is to conduct a Phase II double-blind placebo controlled randomized clinical trial comparing the efficacy of two CBD oil formulations (CBD Isolate (300 mg/day) and CBD Broad Spectrum versus Placebo Oil.

CBD/Placebo Dosing:

Nightly dosing of a hemp-derived formulation of purified CBD isolate (300 mg), CBD Broad Spectrum (300 mg.) or matching placebo oil daily for 8 weeks. Individual doses of both CBD formulations and placebo oil will be provided in identical individual plastic syringes. All patients, PI, and staff who interact with study participants will be blind to participants' assigned treatment condition.

Clinical Assessment Schedule:

Week 0 - Pre-Treatment Screening Visit: All enrolled study participants will complete from their home a clinical assessment battery consisting of self-report rating scales over the Internet (see measures).

Treatment Visits (Weeks 1 - 8): During this phase, all study participants will (a) receive via USPS their weekly allotment of CBD/Placebo oil; (b) complete weekly clinical status assessments via the Internet (see measures).

Posttreatment Assessment Visit (Week 9): All participants will complete an online battery of clinical outcome measures identical to those administered during their pre-treatment visit (see outcome measures).

1-Month Follow-up Assessment Visit (Week 13): All participants will be re-administered the complete battery of primary and secondary outcome measures (see outcome measures).

Outcome Measures

Primary Clinical Outcomes: The primary clinical outcome will be scores on the PTSD Checklist for DSM-5 (PCL-5). Models will be coded to test differences between (1) CBD Isolate + Broad Spectrum vs. Placebo and (2) CBD Isolate vs CBD Broad Spectrum at the primary endpoint (post-treatment) and secondary endpoint (1-month follow-up).

Secondary Clinical Outcomes: Several additional psychiatric outcomes will be assessed at post treatment and follow-up. These clinical outcomes and their respective measures appear below.

  • Depression (PHQ-9)
  • Disability (SDS)
  • Quality of Life (WHOQOL-BREF)
  • Anxiety (GAD-7)
  • Alcohol Use (PROMIS Alcohol Use -Short Form).

Data Management Data Management involves development of methods for ensuring that data collection instruments are programmed; data are properly collected; participants are tracked and monitored over the course of the study; data sets are documented and maintained; variables are created and documented; and main analyses are conducted. To enhance quality control, all data for the current study including demographic information, diagnoses, and participant and clinician rated measures will be directly entered into a HIPAA-compliant electronic case report form (eCRF) using Qualtrics - a secure cloud-based platform designed exclusively for supporting HIPAA compliant data capture and storage. Qualtrics provides: (a) An intuitive interface for data entry with data validation; (b) Audit trails for tracking data manipulation and export procedures; (c) Procedures for importing data from external sources; (d) Automated export procedures for seamless data downloads to common statistical packages (SPSS, SAS, Stata, R) to facilitate data analysis; (e) automated and secure data back-up and storage to servers housed at the University of Texas Population Research Center (PRC). Dr. Telch in his role as Principal Investigator will serve as the Senior data manager and will meet bi-weekly with the research staff on issues related to data management.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Texas
      • Austin, Texas, United States, 78712
        • Laboratory for the Study of Anxiety Disorders, University of Texas at Austin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Meets for a current DSM-5 diagnosis of PTSD as their "primary" mental disorder
  2. Age 18 or older
  3. Fluent in English
  4. Has access to the internet
  5. Willingness to provide signed informed consent
  6. Willingness to refrain from all non-study cannabis use during the study period

Exclusion Criteria:

  1. History of a suicide attempt within the past 6 months
  2. History of psychosis within the past 6 months
  3. History of current alcohol or substance use disorder within the past month
  4. Any medical problems that would preclude participating in the study
  5. History of adverse reaction to CBD oil or other CBD products
  6. Allergy to coconut oil

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: CBD Isolate
300 mg/day of CBD isolate
Drug: CBD Isolate
A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
Other Names:
  • CBD Isolate Oil
Active Comparator: CBD Broad Spectrum
300 mg/day of CBD Broad Spectrum Oil
Other: CBD Broad Spectrum
A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
Other Names:
  • CBD Broad Spectrum Oil
Placebo Comparator: Placebo oil
Matched Placebo Oil
Other: Placebo oil
Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
Other Names:
  • PLBO

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PCL-5
Time Frame: Post-treatment (week 9) and one month (week 13) follow-up assessments
Change from baseline in patient-rated symptoms of PTSD.
Post-treatment (week 9) and one month (week 13) follow-up assessments

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PHQ-9
Time Frame: Post-treatment (week 9) and one month (week 13) follow-up assessments
Change from baseline in patient-rated symptoms of depression.
Post-treatment (week 9) and one month (week 13) follow-up assessments
SDS
Time Frame: Post-treatment (week 9) and one month (week 13) follow-up assessments
Change from baseline in overall disability.
Post-treatment (week 9) and one month (week 13) follow-up assessments
WHOQOL-BREF
Time Frame: Post-treatment (week 9) and one month (week 13) follow-up assessments
Change from baseline in quality of life.
Post-treatment (week 9) and one month (week 13) follow-up assessments
GAD-7
Time Frame: Post-treatment (week 9) and one month (week 13) follow-up assessments
Change from baseline in patient-rated symptoms of anxiety.
Post-treatment (week 9) and one month (week 13) follow-up assessments
PROMIS Alcohol Use -Short Form
Time Frame: Post-treatment (week 9) and one month (week 13) follow-up assessments
Change from baseline in patient-rated alcohol use.
Post-treatment (week 9) and one month (week 13) follow-up assessments

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Texas at Austin

Investigators

  • Principal Investigator: Michael J Telch, Ph.D., University of Texas at Austin

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2020

Primary Completion (Estimated)

May 1, 2024

Study Completion (Estimated)

May 1, 2025

Study Registration Dates

First Submitted

December 10, 2019

First Submitted That Met QC Criteria

December 10, 2019

First Posted (Actual)

December 12, 2019

Study Record Updates

Last Update Posted (Actual)

November 22, 2023

Last Update Submitted That Met QC Criteria

November 17, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-05-0123

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder

Clinical Trials on CBD Isolate

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe